Keros Therapeutics在2000万美元里程碑后启动500万美元股票回购

2026-09-09 04:09

Keros Therapeutics (KROS) announced on Tuesday that its board approved a $5M share repurchase program for its common stock.
The buyback follows a $20M development milestone payment from Takeda Pharmaceuticals (TAK) U.S.A. after the first patient was dosed in the ELRiSE MDS trial for elritercept.
The company may repurchase shares occasionally in the open market or through other permitted methods, depending on market conditions.
The company said the program may be modified, suspended, or discontinued at any time and does not require it to repurchase any specific amount.
On the market side, the stock traded ~2% higher at ~$11.39 in the after-hours trading session.
Source: Press Release

More on Keros Therapeutics